
    
      The third arm of the study (Aprepitant 250 mg) will only be conducted if the real-time
      assessment of the NK1-receptor occupancy data between fosaprepitant 150 mg & aprepitant 165
      mg reveals that the primary hypothesis will not be supported.
    
  